Dr. Robert Rhoads, professor and emeritus chairman of the Department of Biochemistry and Molecular Biology at LSU Health Shreveport, developed key components of the mRNA over years of work. The vaccine uses messenger RNA, or mRNA, which essentially provides instructions to the body on how to fight the novel coronavirus.
The School of Graduate Studies helps to train future scientists and our Centers further elevate our institution's research portfolio. The Office of Research helps support these endeavors and is comprised of the Clinical Trials Office, the Office of Sponsored Programs and Technology Transfer, Human Research Protections Program (HRPP) and the Institutional Review Board (IRB).
Research funding continues to grow on our campus with well over $10 million in the last fiscal year. Videos below outline the new patents, grants and clinical trials taking place on our campus.
“It is gratifying to see LSU Health Shreveport’s contributions to the Pfizer-BioNTech vaccine through licensing of a LSUHS patent to BioNTech for mRNA-stabilizing cap analogs and in serving as the only north Louisiana vaccine trial site. Additionally our numerous COVID-19 clinical trials are providing access to novel therapies reflecting the benefit of having an academic medical center in our community,” shared GE Ghali, DDS, MD, FACS, FRCS (Ed), chancellor of LSU Health Shreveport.
KSLA12- “If the EVT Lab had not existed, quite frankly, I think we’d be in a much darker place here in the northern part of the state,” said Dr. Chris Kevil, vice chancellor of research and one of the leading minds behind creation of the lab. “The EVT Lab has been fundamental in our ability to monitor COVID infections in patients out in this community."
Dr. Quyen Chu, Professor of Surgery and Chief of the Division of Surgical Oncology at LSU Health Shreveport, is the lead author of the study set for publication in an upcoming issue of Cancer, a journal of the American Cancer Society.
SHREVEPORT, La. (KSLA) - Cancer patients from across Northwest Louisiana — who are receiving treatment at MD Anderson Cancer Center in Houston — could soon benefit from new trials closer to home.
The Feist-Weiller Cancer Center is excited to be a part of the Cancer Focus Fund to bring the latest new cancer clinical trials to our community," said Dr. Chris Kevil, Vice-Chancellor for Research at LSU Health Shreveport. "We are confident our clinical trial facilities, coupled with expanded patient access to clinical trials across north and central Louisiana in partnership with Ochsner Health, will yield promising results for all citizens of Louisiana.
The Emerging Viral Threat (EVT) Lab at LSU Health Shreveport has now sequenced a total 651 Louisiana SARS-CoV-2 virus genomes making them the largest contributor to date of genetic data on SARS-CoV-2 in the state. SARS-CoV-2, which is short for ‘Severe Acute Respiratory Syndrome Coronavirus-2,’ is the virus that causes COVID-19, and viral genome sequencing is contributing to a worldwide effort to fight the ongoing pandemic.
The Emerging Viral Threat Lab at LSU Health Shreveport has processed over 110,000 COVID-19 test samples from multiple public health regions of the state and created over 170,000 test kits which were distributed throughout the state during its first six months of operation.
LSUHS is expanding enrollment in the Pfizer-sponsored COVID-19 vaccine study for the next two weeks to include individuals ages 16-18 and those older than 85 years of age. Those interested in participating in this important vaccine trial should sign up as quickly as possible.
The Science & Medicine Academic Research Training Program provides academically advanced high school seniors who are interested in careers related to medicine, scientific research, and biomedical engineering opportunities to engage in intensive research with medical clinicians, researchers, and academic staff.